Publications

Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

All years 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response
  • Easy

Frequency of NRAS gene mutations among the patients with wild type KRAS colorectal cancers in Southern-Eastern Serbia

  • Easy

Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19

  • Easy

Comparison of Allplex™ SARS-CoV-2 Assay, Easy SARS-CoV-2 WE and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19

  • Easy, Myriapod

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

  • Easy, Myriapod

Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study

  • Easy

COVID-19 autopsy cases: detection of virus in endocrine tissues

  • Easy

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.

  • Easy

Fine-Needle Aspiration Cytology and Histological Types of Thyroid Cancer in the Elderly: Evaluation of 9070 Patients from a Single Referral Centre

  • Easy

Francesco Cortiula et. al., A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients

  • Easy

Roberta Minari et. al., Detection of EGFR-Activating and T790M Mutations by Liquid Biopsy in Patients with EGFR-Mutated Non-Small-Cell Lung Cancer Who Have Progressed to First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study

Your next step starts here. Fill out the form and talk to us

Let's talk